Oncology & Cancer

Study identifies new drug target in deadly form of leukemia

A research team led by the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore has identified ways to inhibit the function of a key protein linked to stem cell-like behavior in terminal-stage chronic myeloid leukemia ...

Oncology & Cancer

To beat leukemia, boost cell signaling, study suggests

A new study of acute lymphoblastic leukemia (ALL) led by UC San Francisco researchers puts an intriguing new twist on anti-cancer strategies. Rather than inhibiting cellular signals that arise from a cancer-driving gene—the ...

Oncology & Cancer

Genetic test classifies kidney cancer

Singaporean researchers have developed a genetic test that can reliably identify different subtypes of a specific kind of kidney cancer. The test has the potential to improve treatment, as it can assess a patient's prognosis ...

Oncology & Cancer

Reasons for TKI discontinuation ID'd in chronic myeloid leukemia

(HealthDay)—For patients with chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) therapy can be safely discontinued and yields high rates of treatment-free remission (TFR), according to a study published online ...

Oncology & Cancer

Pazopanib shows better quality-of-life in advanced kidney cancer

Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer ...

Oncology & Cancer

Afatinib improves progression-free survival in head and neck cancer

The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based ...

page 9 from 26